GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: LYT-100
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Deupirfenidone is a deuterated version of the anti-fibrotic drug pirfenidone. Like its parent it inhibits production of pro-inflammatory mediators, including interleukin-6 (IL-6), tumor necrosis factor α (TNFα) and transforming growth factor β (TGFβ).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| LYT-100 has been entered into clinical studies to evaluate its ability to reduce lung fibrosis in idiopathic pulmonary fibrosis (IPF) and long COVID-19. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT04652518 | LYT-100 in Post-acute COVID-19 Respiratory Disease | Phase 2 Interventional | PureTech | ||
| NCT05321420 | LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 Interventional | PureTech | ||